Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions.

Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Markowitz LE; HPV-IMPACT Working Group.

Cancer Causes Control. 2012 Feb;23(2):281-8. doi: 10.1007/s10552-011-9877-6. Epub 2011 Nov 23.

PMID:
22108842
2.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

3.

Expression of p16INK4A in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines.

Badiga S, Chambers MM, Huh W, Eltoum IA, Piyathilake CJ.

Cancer. 2016 Dec 1;122(23):3615-3623. doi: 10.1002/cncr.30229. Epub 2016 Aug 1. Erratum in: Cancer. 2017 Aug 15;123(16):3198.

PMID:
27479745
4.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
5.

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.

Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE.

Vaccine. 2012 Dec 17;31(1):109-13. doi: 10.1016/j.vaccine.2012.10.092. Epub 2012 Nov 6.

PMID:
23137842
6.

The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer.

Muñoz N, Bosch FX.

Bull Pan Am Health Organ. 1996 Dec;30(4):362-77. Review.

PMID:
9041748
7.

Cervical cancer vaccine development.

Frazer IH.

Sex Health. 2010 Sep;7(3):230-4. doi: 10.1071/SH09132. Review.

PMID:
20719210
8.

[Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].

Friedek DA, Ekiel AM, Martirosian G.

Wiad Lek. 2007;60(1-2):34-8. Review. Polish.

PMID:
17607966
9.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
10.

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.

Clin Cancer Res. 2002 Dec;8(12):3676-85.

11.

The impact of preventive HPV vaccination.

Roden R, Monie A, Wu TC.

Discov Med. 2006 Oct;6(35):175-81. Review.

12.

Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.

Budd AC, Sturrock CJ.

Sex Health. 2010 Sep;7(3):328-34. doi: 10.1071/SH09133.

PMID:
20719223
13.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309.

PMID:
19236277
15.

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.

Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Muñoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, Esser MT, Giacoletti K, James M, Taddeo F, Vuocolo S, Barr E.

J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1147-55. doi: 10.1111/j.1468-3083.2009.03266.x. Epub 2009 Apr 23.

PMID:
19453788
16.

Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?

Saleem A, Tristram A, Fiander A, Hibbitts S.

Minerva Med. 2009 Dec;100(6):503-23. Review.

PMID:
20010484
17.

Monitoring the impact of a national HPV vaccination program in Japan (MINT Study): rationale, design and methods.

Matsumoto K, Yaegashi N, Iwata T, Ariyoshi K, Fujiwara K, Shiroyama Y, Usami T, Kawano Y, Horie K, Kawano K, Noda K, Yoshikawa H; MINT Study Group.

Jpn J Clin Oncol. 2014 Oct;44(10):1000-3. doi: 10.1093/jjco/hyu097. Epub 2014 Aug 6.

PMID:
25098705
18.

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.

FUTURE II Study Group.

J Infect Dis. 2007 Nov 15;196(10):1438-46. Epub 2007 Oct 31.

PMID:
18008221
19.

[Diseases caused by human papilloma viruses].

Zollner U, Schwarz TF.

Dtsch Med Wochenschr. 2011 May;136(20):1067-72. doi: 10.1055/s-0031-1275845. Epub 2011 May 10. Review. German.

PMID:
21560109
20.

Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.

Harper DM.

Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7. doi: 10.1016/j.ygyno.2008.06.029. Epub 2008 Jul 22.

PMID:
18649932

Supplemental Content

Support Center